Structure-based design of selective salt-inducible kinase (SIK) inhibitors
R. Tesch, M. Rak, M. Raab, L. M. Berger, T. Kronenberger, A. C. Joerger, B. T. Berger, I. Abdi, T. Hanke, A. Poso, K. Strebhardt, M. Sanhaji, S. Knapp
This study designs a selective SIK inhibitor, MRIA9, based on a PAK inhibitor, showing its dual activity and potential for combination therapy in ovarian cancer.
bioRxiv · Apr 8, 2021 · PreprintBiochemistry